PharmaCell Announces Agreement to be The European CMO for Dendreon
News Oct 24, 2013
PharmaCell has announced that it has entered into an agreement with Dendreon Corporation to be the Contract Manufacturing Organization (CMO) for the European commercial production of its recently approved cellular immunotherapy product Provenge® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) dispersion for infusion.
In September, the European Commission (EC) granted marketing authorization for Provenge in the European Union for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.
In the United States, Provenge was approved in 2010 and is produced by Dendreon in its own manufacturing facilities.
Alexander Vos, chief executive officer of PharmaCell B.V. said, “We are extremely pleased that an immunotherapy industry leader such as Dendreon has decided to continue its relationship with PharmaCell. We have worked with Dendreon since 2011, and the decision to extend our relationship is a testament to the dedication and expertise of our team who have worked with Dendreon throughout the Technology Transfer and European approval process over the past few years.”
Doctors Rely on More Than Just Data During a DiagnosisNews
Computer scientists examine how a doctor’s “gut feeling” influences how many tests they order for patientsREAD MORE
Working Together Helps Phage Overcome CRISPRNews
Surprising results show that phage join forces to overcome bacteria’s CRISPR -based immune defenses. Improved understanding of the interactions between phage and their bacterial hosts could help advance phage-based therapies and stimulate viral research.READ MORE
Study in Mouse Model of Autism Finds Mother's Microbiome Determines RiskNews
The microbiome is the collection of microorganisms, such as bacteria, that naturally live inside us. New research in a mouse model suggests the microbiome determines autism risk.READ MORE